Journal of Clinical and Aesthetic Dermatology

APR 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/811500

Contents of this Issue

Navigation

Page 44 of 64

45 JCAD journal of clinical and aesthetic dermatology April 2017 • Volume 10 • Number 4 REFERENCES 1. Guy G, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–187. 2 . Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–550. 3. What are the key statistics about basal and squamous cell skin cancers? American Cancer Society. http://www.cancer.org. Accessed on March 11, 2016. 4. Habif T. Premalignant and malignant nonmelanoma skin tumors. In: Habif T. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. Mosby Elsevier Inc; 2009:804–831. 5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology; basal cell skin cancer. http://www.nccn.org. Accessed on January 4, 2017. 6. Wolf D, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol Res. 1987;123:340–344. 7. Sterry W. European Dermatology Forum Guideline Committee. Guidelines: the management of basal cell carcinoma. Eur J Dermatol. 2006;16(5):467–475. 8. Telfer N, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008; 159:35–48. 9. Dandurand M, Petit T, Martel P, et al. Management of basal cell carcinoma in adults clinical practice guidelines. Eur J Dermatol. 2006; 16(4):394–401. 10. European Dermatology Forum. Guideline on the treatment of basal cell carcinoma. http://www.euroderm.org. Accessed o n December 10, 2016. 11. Kuijpers D, Thissen MR, Neumann MH. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol. 2002; 3(4):247– 259. 12. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol. 1991;17(7):574–578. 13. Basal cell carcinoma, squamous cell carcinoma (and related lesions)—a guide to clinical management in Australia. Cancer Council Australia and Australian Cancer Network. 2008. 14. Paoli J, Larko O. Actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Clinical Guidelines, Sweden. Forum for Nord Derm Ven. 2009;14(3):71–77. 15. Brodland D, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992; 27:241–248. 16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology; squamous cell skin cancer. http://www.nccn.org. Accessed on November 28, 2016. 17. European Dermatology Forum. Guideline on the diagnosis and treatment of invasive squamous cell carcinoma of the skin. http://www.euroderm.org. Accessed on January 12, 2017. 18. Breuninger H, Eigentler T, Bootz F, et al. Brief guidelines—cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges. 2012;10(Suppl 6):51–58. 19. Motley R, Preston PW, Lawrence CM, et al. Multi-progressional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J D ermatol. 2002;146(1):1–34. 20. Mohs F, Snow SN. Microscopically controlled surgical treatment for squamous cell carcinoma of the lower lip. Surg Gynecol Obstet. 1985;160(1):37–41. 21. Mohs F. Chemosurgical treatment of cancer of the ear: a microscopically controlled method of excision. Surgery. 1947;21(5):605–622. 22. Mohs F. Chemosurgical treatment of cancer of the lip: a microscopically controlled method of excision. Arch Surg. 1944; 48:478–488. 23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology; dermatofibrosarcoma protuberans. http://www.nccn.org. Accessed on December 5, 2016. 24. Kreicher K, Kurlander DE, Gittleman HR, et al. Incidence and survival of primary dermatofibrosacroma protuberans in the United States. Am Soc Dermatol Surg. 2015;42:S24– S31. 25. Sandberg A, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet. 2003;140(1):1–12. 26. McArthur G, Demetri GD, Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exporation consortium study B2225. J Clin Oncol. 2005;23(4):866–873. r E v i E W

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - APR 2017